Why the study?
To establish a reliable cell source to study the effects of KCNQ1 mutation in disease-specific cell types for long QT syndrome type 1.
The establishment of these patient-derived iPSC lines provides a reliable in vitro model to study the mechanisms of KCNQ1 mutations in long QT syndrome type 1.
Patient-derived iPSC lines enable LQTS1 mechanism studies; leaves open clinical translation pending validation.
Long QT syndrome type 1 (LQT1) is a rare heart disorder caused by a loss-of-function mutation in the KCNQ1 gene that causes loss of Kv7.1 channel function, which can lead to Palpitations, Syncope, and Sudden cardiac arrest. We derived induced pluripotent stem cells from PBMC of LQT1 patients carrying a pathogenic variant (c.734G>A; p.Gly245Glu). The non-integrative Sendai virus-mediated iPSC reprogramming method was used for iPSC line generation. These iPSC cell lines exhibit stem cell pluripotency, differentiation capability, and cell morphology, resulting in a reliable cell source to study the effects of KCNQ1 mutation in disease-specific cell types.
No takes yet. Share an insight, caveat, or question.
Mun et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: